Questionnaire

1. ADA/EASD treatment guidelines for type 2 diabetes patients with established CVD or chronic kidney disease (CKD) recommends the use of which of the following agents?

2. ADA/EASD treatment guidelines for patients, like Zahra, without established CVD or CKD:

3. Among non-insulin glucose-lowering therapies, which is the most effective class of agents in lowering GLP-1RA?

4. Which of the following factors are related to improved patient adherence?

5. Current SEMDSA Guidelines for the introduction of insulin in the course of type 2 diabetes treatment regards HbA1c levels as being indicative:

6. Which factors would you consider as you decide on Zahra’s next therapy?

7. What HbA1c target would you wish to achieve with your envisaged treatment?

8. If you consider adding a fourth oral agent, what level of HbA1c reduction would you expect to achieve in Zahra’s case?

9. If you consider adding a GLP-1 agonist what level of HbA1c reduction would you expect to achieve?

10. What would you finally consider to be the best choice for Zahra?